Fundraising Fox
/Companies
Sign in

Vivace Therapeutics

San Mateo, US · Founded 2014 · Delaware corporation · 4 known investors

Find your way into Vivace Therapeutics

Sign up to see every warm intro you have to Vivace Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Vivace Therapeutics team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.

BiotechHealthtechMedical Devices

Founders & leadership

Vivace Therapeutics was founded in 2014 by Shuang Qiao.

SQ
Shuang QiaoFounder
SD
Sheng DingNamed on SEC filing
SQ
Sofie QiaoFounder

Board

EH
Edward HuBoard director
JWJun Wu
Jun WuBoard directorChairman and Managing Partner at Cenova Capital
JSJake Simson
Jake SimsonBoard directorPartner at RA Capital
TSTim Shannon
Tim ShannonBoard directorGeneral Partner at Canaan Partners
CZ
Chenguang ZhouBoard director

Investors · 4

RA Capital✓ confirmed by Vivace TherapeuticsBoston

How we know: the company's own site · RA Capital's portfolio page · funding news · pharmexec.com · Not right? Tell us

Cenova Capitallisted by Cenova CapitalShanghai

How we know: pharmexec.com · Not right? Tell us

Mission Biocapitallisted by Mission BiocapitalSan Francisco · $500K

How we know: Mission Biocapital's portfolio page · the VCSheet dataset · Not right? Tell us

Funding

SEC filings, press & company announcements

$95.5M disclosed across 5 rounds · 2015–2026

▶$17.5MraisedMar 2025 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward HuDirector
  • Jun WuDirector
  • Jake SimsonDirector
  • Tim ShannonDirector
  • Chenguang ZhouDirector
  • Shuang QiaoExecutive Officer, Director
Offering amount
$35M
Amount sold
$17.5M
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedDec 2020 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shuang QiaoExecutive Officer, Director
  • Edward HuDirector
  • Leonard PostDirector
  • Tim ShannonDirector
  • Jun WuDirector
  • Chenguang ZhouDirector
Offering amount
$30M
Amount sold
$30M
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedMay 2018 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Leonard PostExecutive Officer, Director
  • Shuang QiaoExecutive Officer, Director
  • Edward HuDirector
  • Tim ShannonDirector
  • Jun WuDirector
Offering amount
$25M
Amount sold
$8M
First sale
May 2017
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedJan 2015 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Shuang QiaoExecutive Officer, Director
  • Edward HuDirector
  • Tim ShannonDirector
  • Sheng DingExecutive Officer
Offering amount
$15.1M
Amount sold
$5M
First sale
Jan 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as Vivace Therapeutics.

In the news

Vivace Therapeutics Raises $35 Million in Series D Financing to Support Clinical Development of First-in-Class Cancer Drug Targeting the Hippo Pathwayprnewswire.com · Mar 2025

Frequently asked questions

What does Vivace Therapeutics do?
Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.
Who founded Vivace Therapeutics?
Vivace Therapeutics was founded by Shuang Qiao in 2014.
Who are Vivace Therapeutics's investors?
Vivace Therapeutics's investors include Canaan Partners, RA Capital, Cenova Capital, Mission Biocapital.
How much funding has Vivace Therapeutics raised?
Vivace Therapeutics has disclosed $95.5M raised across 5 rounds.
Where is Vivace Therapeutics headquartered?
Vivace Therapeutics is headquartered in San Mateo, US.